Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Gains from Investment Securities (2022 - 2025)

Stoke Therapeutics (STOK) has 4 years of Gains from Investment Securities data on record, last reported at $407482.0 in Q2 2025.

  • For Q2 2025, Gains from Investment Securities fell 54.61% year-over-year to $407482.0; the TTM value through Jun 2025 reached $407482.0, down 54.61%, while the annual FY2024 figure was $8.0 million, 23.41% up from the prior year.
  • Gains from Investment Securities reached $407482.0 in Q2 2025 per STOK's latest filing, down from $2.0 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $8.3 million in Q4 2022 and bottomed at $79400.0 in Q3 2022.
  • Average Gains from Investment Securities over 4 years is $2.3 million, with a median of $998356.0 recorded in 2024.
  • Peak YoY movement for Gains from Investment Securities: surged 657.01% in 2024, then plummeted 54.61% in 2025.
  • A 4-year view of Gains from Investment Securities shows it stood at $8.3 million in 2022, then fell by 21.71% to $6.5 million in 2023, then rose by 23.41% to $8.0 million in 2024, then crashed by 94.9% to $407482.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were $407482.0 in Q2 2025, $2.0 million in Q1 2025, and $8.0 million in Q4 2024.